Sitagliptin phosphate: A DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

Clinical Therapeutics

Volumn 29, Issue 12, 2007, Pages 2614-2634

  Zerilli, Tina ^a   Pyon, Eunice Y ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

dipeptidyl peptidase 4; MK 0431; sitagliptin; type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CYCLOSPORIN; DIGOXIN; EXENDIN 4; GLIBENCLAMIDE; GLIPIZIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; ROSIGLITAZONE; SIMVASTATIN; SITAGLIPTIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE;

ABDOMINAL PAIN; ADD ON THERAPY; ALKALINE PHOSPHATASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; EDEMA; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH SERVICE; HEART PALPITATION; HOMEOSTASIS; HUMAN; HYPERSENSITIVITY; HYPERTENSION; HYPOGLYCEMIA; INSULIN RELEASE; KETOACIDOSIS; LEUKOCYTE; LIVER METABOLISM; MEDLINE; MONOTHERAPY; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OSTEOARTHRITIS; PAIN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PHARYNGITIS; PROTEIN FUNCTION; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SORE THROAT; SUICIDE ATTEMPT; THORAX PAIN; TIME SERIES ANALYSIS; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; URTICARIA; VOMITING;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR STRUCTURE; PYRAZINES; TRIAZOLES;

EID: 38049065376     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.12.034     Document Type: Article

References (48)

1. World Health Organization. Diabetes [WHO Web site]. WHO fact sheet no. 312 (April 14, 2007). http://www.who.int/mediacentre/factsheets/fs312/en/ Accessed
2. American Diabetes Association. The Dangerous Toll of Diabetes. [ADA Web site] (April 14, 2007). http://diabetes.org/diabetes-statistics/dangerous-toll.jsp Accessed
3. Hogan P., Dall T., Nikolov P., and American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 26 (2003) 917-932
4. Nathan D., Buse J., Davidson M., et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement for the American Diabetes Association and the European Association for the Study of Diabetes. [published correction appears in Diabetes Care. 2006;49:2816-2818]. Diabetes Care 29 (2006) 1963-1972
5. Januvia (sitagliptin) [package insert] (2006), Merck & Co, Inc, Whitehouse Station, NJ
6. Drucker D., and Nauck M. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
7. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 60 (2006) 1454-1470
8. Toft-Nielsen M., Damholt M., Madsbad S., et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86 (2001) 3717-3723
9. Lambeir A., Durinx C., Scharpe S., and De Meester I. Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40 (2003) 209-294
10. Kim D., Wang L., Beconi M., et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48 (2005) 141-151
11. Lankas G., Leiting B., et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 54 (2005) 2988-2994
12. Beconi M., Reed J., Teffera Y., et al. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab Dispos 35 (2007) 525-532
13. Vincent S., Reed J., et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 35 (2007) 533-538
14. Herman G., Stevens C., Van Dyck K., et al. Pharmaco-kinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78 (2005) 675-688
15. Bergman A., Stevens C., Zhou Y., et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 28 (2006) 55-72
16. Narita H., Nonaka K., Stevens C., et al. Multiple dose administration of sitagliptin, a dipeptidyl peptide IV (DPP-4) inhibitor, in healthy Japanese subjects. Presented at:. American Diabetes Association 66th Annual Scientific Sessions. Washington, DC (June 9-13, 2006) Abstract 533-P
17. Herman G., Bergman A., Stevens C., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91 (2006) 4612-4619
18. Liu D., Arison B., Stearns R., et al. Characterization of two cyclic metabolites of sitagliptin. Drug Metab Dispos 35 (2007) 521-524
19. Chu X., Bleasby K., Yabut J., et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 321 (2007) 673-683
20. Bergman A., Cote J., Yi B., et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 30 (2007) 1862-1864
21. Stevens C., Bergman A., Liu Q., et al. Lack of clinically significant effect of moderate hepatic insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a dipeptidyl-peptidase-IV (DPP-IV) inhibitor. Clin Pharmacol Ther. 79 (2006) P49 Abstract PII-49
22. Bergman A., Stevens C., Yi B., et al. Lack of a clinically meaningful effect on age, gender or obesity on the pharmacokinetics of the DPP-IV inhibitor MK-0431. Presented at:. American Diabetes Association 65th Annual Scientific Sessions. San Diego, Calif. (June 10-14, 2005) Abstract 2101-PO
23. Herman G., Bergman A., Liu F., et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 46 (2006) 876-886
24. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85 (1999) 9-24
25. Faidley T., Leiting B., et al. Inhibition of dipeptidyl-peptidase IV does not increase circulating IGF-1 concentrations in growing pigs. Exp Biol Med 231 (2006) 1373-1378
26. Meece J. Pancreatic islet dysfunction in type 2 diabetes: A rational target for incretin-based therapies. Curr Med Res Opin 23 (2007) 933-944
27. Mu J., Woods J., Zhou Y., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 (2006) 1695-1704
28. Mu J., Zhou Y.-P., Woods J., et al. Direct comparison of efficacy and durability of DPP-4 inhibitor, PPAR agonist and sulfonylurea on glycemic control and β-cell function in a rodent model of type 2 diabetes. Presented at:. American Diabetes Association 66th Annual Scientific Sessions. Washington, DC (June 9-13, 2006) Abstract 588-P
29. Xu L., Dalla Man C., Cobelli C., et al. Sitagliptin improved beta-cell function in patients with type 2 diabetes (T2DM): A model-based analysis. Presented at:. American Diabetes Association 66th Annual Scientific Sessions. Washington, DC (June 9-13, 2006) Abstract 2014-PO
30. Scott R., Wu M., Sanchez M., and Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 61 (2007) 171-180
31. Merck & Co, Inc. Januvia (sitagliptin phosphate) 25 qd, 50 qd and 100 mg qd. New Drug Application Statistical Review and Evaluation [US Food and Drug Administration Center for Drug Evaluation and Research Web site] (April 11, 2007). http://www.fda.gov/cder/foi/nda/2006/021995s000_StatR.pdf Accessed
32. Merck & Co, Inc. Januvia (sitagliptin phosphate) tablets 25 qd, 50 qd and 100 mg qd. ODE Decisional Review Memorandum [US Food and Drug Administration Center for Drug Evaluation and Research Web site] (April 11, 2007). http://www.fda.gov/cder/foi/nda/2006/021995s000_MedR.pdf Accessed
33. Aschner P., Kipnes M., Lunceford J., et al., Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 (2006) 2632-2637
34. Raz I., Hanefeld M., Xu L., et al., Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49 (2006) 2564-2571
35. Rosenstock J., Brazg R., Andryuk P., et al., Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28 (2006) 1556-1568
36. Brazg R., Xu L., Dalla Man C., et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 9 (2007) 186-193
37. Charbonnel B., Karasik A., Liu J., et al., Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29 (2006) 2638-2643
38. Nauck M., Meininger G., Sheng D., et al., Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 9 (2007) 194-205
39. Goldstein B., Feinglos M., Lunceford J., et al., Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30 (2007) 1979-1987
40. Scott R., Hartley P., Luo E., et al. Use of sitagliptin in patients with type 2 diabetes (T2DM) and renal insufficiency (RI). Presented at:. American Diabetes Association 66th Annual Scientific Sessions. Washington, DC (June 9-13, 2006) Abstract 1997-PO
41. Wright D., Maes A., Yi B., et al. Multiple dose administration of MK-0431 (sitagliptin), an inhibitor of dipeptidyl peptidase-IV, does not meaningfully alter the plasma pharmaco-kinetics or pharmacodynamics of single doses of warfarin. Clin Pharmacol Ther. 79 (2006) P76 Abstract PIII-64
42. Ruddy M., Bergman A., Zheng W., et al. Sitagliptin, a DPP-4 inhibitor, does not inhibit the pharmacokinetics of the sulfonylurea, glyburide. Presented at:. American Diabetes Association 66th Annual Scientific Sessions. Washington, DC (June 9-13, 2006) Abstract 558-P
43. Mistry G., Bergman A., Luo W., et al. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol 47 (2007) 159-164
44. Bergman A., Cote J., Maes A., et al. Sitagliptin (MK-0431), a selective dipeptidyl-peptidase-IV (DPP-IV) inhibitor, does not affect the pharma-cokinetics of simvastatin in humans. Clin Pharmacol Ther. 79 (2006) P48 Abstract PII-46
45. Miller J., Migoya E., Talaty J., et al. The effect of MK-0431 on the pharmacokinetics of digoxin after concomitant administration for 10 days in healthy subjects. Clin Pharmacol Ther. 79 (2006) P24 Abstract PI-65
46. Krishna R., Bergman A., Larson P., et al. Effect of a single cyclosporine dose on the single-dose pharmaco-kinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol 47 (2007) 165-174
47. Herman G., Bergman A., Yi B., and Kipnes M. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 22 (2006) 1939-1947
48. Red Book: Pharmacy's Fundamental Reference. April 2007 Update (2007), Thomson Healthcare, Montvale, NJ